CNCR - (Loncar Cancer Immunotherapy ETF)

CNCRのニュース

   Top Momentum ETF Plays: MNA, GREK, XPH, CNCR, EWJ, BJK, HEFA  2020/09/16 13:53:33 The Street
Top 25 momentum candidates that are displaying positive price movement, improving relative strength and strong technical signals.
   3 ETFs For More Moderna Bets  2020/05/19 13:29:37 Benzinga
Shares of biotechnology company Moderna Inc (NASDAQ: MRNA ) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress. Those headlines prompted some analysts to say Moderna could be the first to market with a credible vaccine for the sometimes-fatal respiratory illness, and with those comments came at least a trio of bullish price target revisions into triple-digit territory. For all the ebullience surrounding Moderna this year — and there's been plenty as highlighted by a 2020 climb of 309% — the stock isn't often mentioned in relation to exchange traded funds. A few ETFs have robust Moderna holdings. The stock closed at $80 Monday, and with some price targets residing in the $100 to $105 area, there could be more upside ahead, meaning the following ETFs could be worth considering. Loncar Cancer Immunotherapy ETF (CNCR) Sixty-two ETFs have some exposure … Full story available on Benzinga.com
   A Ripple In Generics?  2019/03/08 21:37:19 Seeking Alpha
   Currents Of Disruption: Focusing On Fundamentals In Biotech  2019/02/08 09:08:31 Seeking Alpha
   Top Momentum ETF Plays: MNA, GREK, XPH, CNCR, EWJ, BJK, HEFA  2020/09/16 13:53:33 The Street
Top 25 momentum candidates that are displaying positive price movement, improving relative strength and strong technical signals.
   3 ETFs For More Moderna Bets  2020/05/19 13:29:37 Benzinga
Shares of biotechnology company Moderna Inc (NASDAQ: MRNA ) jumped 20% Monday on news that its mRNA-1273 coronavirus vaccine candidate is making positive progress. Those headlines prompted some analysts to say Moderna could be the first to market with a credible vaccine for the sometimes-fatal respiratory illness, and with those comments came at least a trio of bullish price target revisions into triple-digit territory. For all the ebullience surrounding Moderna this year — and there's been plenty as highlighted by a 2020 climb of 309% — the stock isn't often mentioned in relation to exchange traded funds. A few ETFs have robust Moderna holdings. The stock closed at $80 Monday, and with some price targets residing in the $100 to $105 area, there could be more upside ahead, meaning the following ETFs could be worth considering. Loncar Cancer Immunotherapy ETF (CNCR) Sixty-two ETFs have some exposure … Full story available on Benzinga.com
   A Ripple In Generics?  2019/03/08 21:37:19 Seeking Alpha
   Currents Of Disruption: Focusing On Fundamentals In Biotech  2019/02/08 09:08:31 Seeking Alpha

calendar